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Abstract
Background Several smartphone applications aim at facilitating communication between patients and healthcare providers. In
this review, we evaluate and compare the most promising applications in the field of diabetes mellitus (DM) and obesity. Most
applications monitor body weight, fasting or postprandial blood glucose, glycosylated hemoglobin (Hgb) A1c (HgbA1c), and
units and types of insulin used.
Methods Nine clinically tested applications and two Web platforms were grouped into three categories that were evaluated and
compared. Group 1 included seven applications focusing mainly on monitoring DM, fitness and weight, blood glucose levels,
and HbA1c. Group 2 included two applications that focus on insulin dosage calculators and glucose self-monitoring tests. Group
3 included two web-platforms that interact with patients via SMS (short message service) messaging.
Results A common feature of the applications examined was the limited number of clinical parameters tested, the small number
of subjects taking part in the evaluation, and the fact that the controls were not randomized. Furthermore, the interfaces of the
applications varied and were not standardized. Finally, another common characteristic across applications was the lack of
standardization of the interface and the overall structure due to language barriers, the devices usually having been designed
around a specific language. Lastly, most applications lacked a critical mass of evaluators and were thus not worthy of being
considered of serious clinical relevance.
Conclusions The current smartphone applications for DM are characterized by a limited number of participants, a small number
of parameters, and a lack of standardization.
Keywords Diabetes . Insulin .Mobile applications
Introduction
In 2015, in the UK, approximately 3.8 million people aged
over 16 (about 9% of the adult population) were suffering
from diabetes mellitus type 2 (T2DM) (https://www.gov.uk/
government/news/38-million-people-in-england-now-have-
diabetes, https://www.diabetes.org.uk/Preventing-Type-2-
diabetes/Prevention/, http://www.diabetes.co.uk/diabetes-
prevalence.html). Moreover, 11.9 million were at increased
risk of developing insulin resistance and type 2 diabetes. It is
also estimated that worldwide, around 220 million persons
have T2DM, a figure that is expected to reach 366 million
by 2030 [1, 2]. Obesity, sedentary lifestyles, and unhealthy
eating habits represent the main causes of T2DM.
Approximately 95% of the daily management of T2DM
depends on the patients themselves making multiple choices
regarding the type of diet consumed, intensity of physical
activity, levels of smoking and alcohol consumption, glucose
monitoring type, and dosage of prescribed drugs, all this with
minimal medical supervision [3, 4]. This requires extensive
knowledge regarding the pathophysiology of T2DM, includ-
ing the effects of the glycemic index (GI) of each food item,
load of food intake (glycemic load), amount of exercise, the
significance of hyper/hypoglycemias, dosage of antidiabetic
medications, and amount and timing of insulin injections. It
also requires problem-solving skills and behavioral changes to
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cope when things become unmanageable, which explains the
increasing need for applications that permit closer interaction
between the diabetic and healthcare-providers.
It should be noted that mobile applications now use GPS
navigation, step trackers (accelerometer sensors), diaries, and
digital cameras. A great number of patients with T2DM own
smartphones in Europe, the USA, Asia, and the developing
world, and very sophisticated phone devices are now widely
affordable [3]. Statistical information about each individual
patient, which is highly important for the management of the
disease, is thus readily available to healthcare providers. There
are number of such applications, including BG Monitor
Diabetes, Diabetes in Check, Diabetes Pilot Pro, Diabetes
Tracker, Diabetic Connect, Glucagon, Glucose Buddy,
mySugr, and Diabetes Logbook, which have been designed
to educate and encourage patients to adopt healthier lifestyles
and to self-monitor their physical exercise, blood pressure,
glucose levels, heart rate, body weight, and insulin dosages.
Unfortunately, the validity of these applications has not been
verified via extensive clinical tests and, consequently, limited
confidence can be placed in their efficacy and safety.
Methodology
To facilitate comparison, the applications have been divided
into three major categories:
– Seven lifestyle self-management applications for T2DM
patients: They mainly focus on monitoring daily caloric
intake, type of food consumed, exercise, fasting blood
glucose (FBG), postprandial glucose (PPG), and type of
medications used. These health apps aim to motivate the
users to adopt better lifestyle habits.
– Two insulin dose calculators for T1DM patients: We
compare the accuracy and clinical suitability of two ap-
plications for calculating treatment, mainly focusing on
insulin calculators for patients with T1DM. Because self-
medication errors are recognized as a source of avoidable
harm, these applications deserve particular scrutiny [5].
– Finally, two text messaging intervention applications for
T2DM patients: Text messaging intervention is an ap-
proach designed to motivate mobile phone users to im-
prove their health by receiving frequent reminders about
exercise and blood tests and about improving the quality
of their diet.
Each application was evaluated for (i) straightforwardness
of installation and compatibility, (ii) clarity of language, (iii)
simplicity of use, (iv) inclusion of daily health monitoring
features, (v) educational value, (vi) sharing data with
healthcare providers, and (vii) effectiveness of the intervention.
Each application was further examined from a statistical
point of view providing to the reader means, standard devia-
tion, and P values (e.g., mean ± SD or % improve/drop) wher-
ever available. The clinical evaluation of each application in-
cludes patients’ fasting glucose levels, PPG levels, changes of
hemoglobin HbA1c levels, and frequent hypoglycemic
events.
Applications for T2DM patients
All of the selected applications conform to the guidelines of
the Food and Drug Administration (FDA) [6].
bant2
The “bant2” application is easy to use, English is the interface
language, and it is available for both Android and Apple de-
vices. It was designed, via Bluetooth connection, to help mon-
itor daily food intake, weight and blood glucose, and HbA1c.
It can also be connected to several external devices and store
the gathered data. We have found that the application exhibits
several shortcomings including the following: (i) it cannot
track caloric intake, which can only be deduced by pictures
of the meals; (ii) the educational value of the interface is se-
verely limited, and most users have commented negatively
regarding it; (iii) its motivational value is limited; therefore,
it may only be used as a tracking or reminding tool; and (iv)
the stored data remain within the device; hence, the healthcare
providers do not have access to the data since the device does
not provide sharing facilities (Fig. 1).
Clinical evaluation of the application A current clinical study
is evaluating “bant2” application on 150 English-speaking
T2DM participants with HbA1c > 7.5%, who do not take
insulin. The principal analysis strategy was based on linear
mixed models in the Statistical Analysis System (Cary, NC,
USA) using the PROC MIXED procedure. The following
parameters will be examined: (i) the effect of the application
on glycemic control, (ii) effect of the application on lifestyle
parameters, (iii) if it facilitates self-care activities, and (iv) if it
improves several biochemical parameters of their diabetes [7,
8]. The clinical trials started in 2015 and are due to be com-
pleted by the end of 2018. Early results suggest that the appli-
cation improved HbA1c levels, blood pressure, cholesterol,
and total weight.
Noom Health
The “Noom Health” mobile application is available only for
English-speaking Android users. In contrast to “bant2,”
“Noom Health” aims at educating users on various aspects
of their disease. Through a combination of automated and
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human interventions, it teaches patients how to sustain their
diet gains and activity levels via (i) a “virtual” coach that
delivers timely, tailored, and motivational guidance; (ii)
trained facilitators who lead “in-app” support groups to bolster
patient engagement; (iii) a 500,000+-item international food
database; and (iv) a color-coded calorie density feedback in-
dicator regarding healthier food choices. It should be noted
that a user wishing to access the application is asked to contact
the “Noom Health” company and request a personalized ID.
The installation process, according to users’ reviews, is rather
cumbersome, as it necessitates a register-activation authenti-
cation process.
Clinical evaluation of the application It was clinically tested in
a pilot study on 62 overweight or obese insulin-resistant adults
who received a 24-week “virtual diabetes prevention” pro-
gram, with human coaching [9]. The main aim of this prelim-
inary evaluation was to test the application’s weight loss effi-
cacy. Samples were compared using the t test between non-
starters and starters. It is of interest that multiple measurement
analysis of variance (ANOVA) showed the effect of time on
weight changes. Backward regression analysis examined
whether engagement variables were able to predict weight loss
at 16 and 24 weeks. In the clinical evaluation tests, eight
participants were excluded from the first week for not follow-
ing the instructions and, of the remaining 54, 36 completed the
full treatment. Ad hoc ANOVA tests indicated that weight loss
was significant at 16 weeks for starters (weight loss = − 5.40,
SD = 4.43, P < 0.001) and completers (weight loss = − 6.00,
SD = 4.34, P < 0.001). Weight loss was also significant at
24 weeks from baseline in starters (weight loss = − 6.22,
SD = 5.00 P < 0.001) and completers (weight loss = − 7.01,
SD = 4.83, P < 0.001). The main limitation of the clinical
evaluation was that it lasted only 6 months and that the par-
ticipants were not examined for persisting insulin resistance,
glucose levels, or HbA1c.
DialBetics
The “DialBetics” application is produced for Japanese-
speaking mobile users as a pilot study by the Japanese
Society for the Promotion of Science and was designed for
T2DM patients to help them with their lifestyle self-
management [10]. This application is similar to “bant2” as it
can be connected via Bluetooth to several external devices for
collecting several parameters, including daily blood glucose
levels, blood pressure, body weight, and pedometer data; ad-
ditionally, the data are not only stored in a calendar but also
automatically transmitted to the Society’s doctors, who advise
on intensive follow-up exercises, or, in cases of abnormal
readings, additional or different treatment modalities.
Clinical evaluation of the application The study of the clinical
efficacy of the application should be considered preliminary,
as a longer study will follow of more participants to validate
the long-term effects. More specifically, this preliminary eval-
uation was composed of two groups in this trial aiming at
determining safety and usability. Group 1 consisted of 54
Fig. 1 The “bant2”mobile application interface aiming in helping T2DM
patients to monitor and maintain normal daily glucose levels. The green
tab (bottom left) monitors steps. The middle tab shows the daily input
statistic. The upper right-hand tab shows the patient’s current weight and
steps activity. The lower right-hand tab shows the user’s daily blood
glucose levels based on food intake and number of exercise sessions
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participants with T2DM who were not on insulin injections,
while ten participants with T2DM in Group 2 were on insulin
treatment. After 3 months, the HbA1c of the first group using
DialBetics was slightly improved, from 7.1 ± 1.0 to 6.7 ±
0.7%. The second group was followed up for only 1 month.
The authors report a reduction of the insulin needed compared
to baseline, but this was based on a limited number of partic-
ipants, while the difference in HbA1c is borderline, from 7.0
± 0.9 to 7.1 ± 1.1% (P = 0.019).
Welltang
The “Welltang” mobile application [11] uses Chinese
(Mandarin) as an interface language for both Apple and
Android devices. It is characterized by three main features:
(i) guidelines giving daily advice about diet, exercise, medi-
cation, how to self-monitor blood glucose levels; (ii) monitor-
ing and measuring medication and assessing lifestyle activity
effectiveness; (iii) daily recordings of diet, physical activities,
glucose levels, and medicine dosages transferred to users’
accounts that are retrievable in the event of mobile failure;
and,(iv) similarly to “DialBetics,” a professional version for
doctors to monitor progress offers advice and information and
adjusts prescriptions and dosages.
Clinical evaluation of the application The clinical evaluation
of the “Welltang” application is considered satisfactory, the
sample consisting of 100 evenly randomized patients with
T2DM between the ages of 18 and 74 recruited for a 3-month
period to test the effectiveness of the application regarding
changes of FBG levels, 2-h PPG, body weight, blood pressure,
low-density lipoprotein (LDL) cholesterol, and frequency of
hypoglycemic events. Statistical analysis was carried out with
the SPSS package (SPSS Inc., Chicago, IL, USA). Prior to
analysis, the distribution variables were tested to ensure that
assumptions of normality were valid. An independent t test
was used to compare the difference between two study groups,
while a paired sample t test was used to compare changes from
baseline to 3-month follow-up. The authors have found a de-
crease of HbA1c by 1.95% in the intervention group and 0.79%
in the control group (P < 0.001). Eighty-four percent of patients
in the intervention group declared their satisfaction with the
application vis-à-vis the user-friendliness aspect.
Diabetes Pal
The advantage of the “Diabetes Pal” (Fig. 2) application is
that it allows T2DM users to transfer glucose monitoring
data either automatically via Bluetooth—such as by the
Telcare BMG device—or manually to data-storing devices,
including mobile devices and/or Web servers, allowing
them to be accessed by healthcare providers. Patients can
also select a specific time period from their diaries. Users’
reviews suggest that it is an easy application to use, while it
can store glucose results and a wide range of medical and
prescription information. Health providers can monitor
their patients’ health status only if patients are willing to
share their health information. It is available for both
Android and Apple devices. The application also helps
with hypoglycemia episodes by guiding the patient via
comprehensive text instructions. The drawback of this ap-
plication is that it can only track FBG levels but does not
store other data, including lifestyle and physical activity,
number of steps, caloric intake data, body weight, or hy-
poglycemic events.
Clinical evaluation of the applicationA 24-week, randomized,
open-label, parallel-group trial was conducted at the
Singapore General Hospital between March 2013 and
March 2015. The study was approved by the ethics board of
the Singapore Health Services.
The first group consisted of 33 insulin-naive T2DM pa-
tients. However, three handicaps can be seen, namely, the
number of participants was small, there was no control group,
and the number biochemical parameters evaluated was small.
All the participants received a one-time individual educational
session with a diabetes nurse educator. The participants were
instructed to start with 10 units of insulin detemir at bedtime,
self-monitor FBG daily, and self-titrate insulin every 3 days
using a prescribed algorithm to reach a target FBG of 72–
126 mg/dL (4.0–7.0 mmol/L). The algorithm was based on
the mean FBG (mFBG) over 3 days (10 units of insulin);
when mFBG exceeded 180 mg/dL, the dose was also
exceeded by 4 units and when mFBG was 126–180 mg/dL
was exceeded by 2 more units. If FBG was < 72 mg/dL, the
dose was reduced by 4 units. Up-titration of insulin dose was
continued until the patient reached the target FBG or the
predetermined maximum insulin dose (0.6 units/kg) allowed
for self-titration (i.e., algorithm end point), whichever oc-
curred first. Patients in the intervention group (n = 33) entered
FBG readings into the app daily; the app responded with a
suggested insulin dose. Each patient’s maximum dose was
preset and locked in the app as a safety measure. It must be
mentioned as limitations that the patients were unable to edit
typographical errors in their FBG inputs, a field for actual
injected dose was not available, and the application was not
usable offline.
The second group consisted of 66 patients. Twenty-two of
them were women; age was 53.3 ± 7.4 years; duration of dia-
betes was 12 ± 8 years; the HbA1c was 9.9 ± 1.8%. The au-
thors found an average drop of HbA1c levels before and after
6 months from 9.9 to 8.8%, with no statistically significant
difference between the groups (P = 0.88) [12]. While most
participants had experienced at least one confirmed hypogly-
cemic event in the past, no new episodes were recorded during
the trial period.
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PilAm Go4Health
The application “PilAmGo4Health” [13] started as an attempt
to evaluate the use of smartphone external devices in the man-
agement of patients with T2DM and, more specifically, how
to help them lose weight. This application is similar to the
“bant2 and DialBetics” applications. It can be connected to
Bluetooth devices, such as Fitbit, which tracks step activities.
It does not store the type of food consumed, total caloric in-
take, and biochemical parameters.
Clinical evaluation of the application This study was a 3-
month-based pilot randomized controlled trial (RCT) with
an active waitlist control and a 3-month maintenance design.
The objective of this trial was to assess the feasibility and
potential efficacy of the PilAm Go4Health intervention to re-
duce risks for metabolic syndrome in Filipinos with T2DM.
Inclusion and exclusion criteria were based on the American
Heart Association metabolic syndrome risks, diagnosis, and
management, as well as the DPP trial. Forty-five T2DM
Filipino-American patients took part. Participants were ran-
domized to an intervention group (n = 22) or active control
group (n = 23), and analyses of the results are underway. The
participants could track and store their daily steps and upload
diet recommendations, recipes, and activity results via a
Facebook group page. The application does not provide edu-
cational information about their condition. Once every
3 months, each participant has to visit the hospital for training,
coaching support, and progress evaluation. To evaluate the
effectiveness of this approach, blood readings were taken in
the third and sixth months, with results showing an average
fall of HbA1c levels from 7.4 to 6.9%. At the start, the average
of body mass index (BMI) was 30.2 + 4.9 and after 6 months
decreased to 28.4 ± 3.3. Comparisons of baseline characteris-
tics demonstrated two statistically significant differences (Pm
< 0.05) between the intervention and control groups.
ONE DROP
The “ONE DROP” is a coaching and educational application
for Apple users, recognized by the American Diabetes
Association. Twelve lessons are provided over a 9-week peri-
od. These lessons are aimed at providing instructions and rec-
ommendations to help the users monitor their health status
daily. It provides the same features as the already mentioned
applications, plus a communication feature via SMS with live
coaching by a certified diabetes educator (CDE) member for
24 h a day/5 days a week. The coach is available for the first
9 weeks’ educational period to answer users’ questions.
Additionally, the user can share his/her personal health records
and achievements with other users in order tomotivate or to be
motivated.
Clinical evaluation of the application One hundred forty-six
patients tested the ONE DROP application for 12 weeks [14].
Seventy-one percent were female and 25% were black or
Hispanic, diagnosed with T2DM. On average, participants
actively used the app on 55 days over the 84-day (12-week)
Fig. 2 The interface of the mobile application Diabetes Pal. The top left tab is the app navigator. On the second tab, the patient can see his/her health
status and activities for a period of 14 days. The panel along the right-hand side shows fasting and postprandial blood glucose levels
Hormones (2018) 17:541–550 545
study period. An active day was defined as a day when the
participant interacted with the application. Of the partici-
pants who completed the final assessment, 94% reported
that the diabetes mobile application with in-app coaching
helped them to manage their diabetes satisfactorily. Overall,
study participants sent an average of 14 messages to their
coaches. Approximately 78% of the participants who com-
pleted the final assessment found the educational content
and lessons helpful, and 73% reported that they thought
their coach was motivating and provided useful strategies.
The two-tailed paired t test and a nonparametric signed-rank
test compared mean and median change in HbA1c from
baseline to study end. The authors reported an improvement
of HbA1c by − 0.86% (P = 0.0003) among study completers
(n = 127), − 0.96% (P < .001) among active users of the app
and coaching program (n = 93), and − 1.32% among active
users with a baseline HbA1c ≥ 9.0% (P < 0.001) (n = 53).
Applications for T1DM patients (insulin dose
calculators)
There are few applications that aim at helping patients with
T1DM to calculate their daily insulin needs. Accurate cal-
culations are based on factors such as (i) current and target
blood glucose, (ii) carbohydrate-to-insulin ratios, (iii) total
grams of carbohydrate in meals, and (iv) insulin already in
the system [15]. However, it is difficult for patients to take
all these factors into account when calculating dosages.
Currently, numerous applications for Android and Apple
devices claim to have such calculations; however, the ma-
jority have not been tested by clinical trials; thus, patients
may risk overdosing or suffering hypoglycemic events. The
following section presents clinically tested smartphone in-
sulin dose calculator applications.
RapidCalc
The application “RapidCalc” (Fig. 3) was designed for
English-speaking Apple device users only. It provides a full
90-day record of insulin doses, carbohydrate intake, and glu-
cose blood readings that can also be exported via email for
archiving or further analysis. Charts and summary statistics
help with blood glucose control, identifying trends, and even
estimating HbA1c. Additionally, by entering blood glucose
and food carbohydrate values, it can suggest meals and
corrected bolus insulin doses. Although it is easy to use, it
has several limitations: it does not (i) provide a database of
food caloric intake, (ii) collect activities tracker data, or (iii)
educate or motivate users.
Clinical evaluation of the application The clinical evaluation
of this application was elementary. Only seven patients with
T1DM took part and for only 4 weeks. The interview group
had previously received a flexible multiple daily injection
(MDI managing complex mathematical calculations to deter-
mine insulin doses) education program by attending the Dose
Adjustment for Normal Eating (DAFNE) program. The
DAFNE program aims to equip graduates with evidence-
based insulin self-management skills based on carbohydrate
counting and insulin algorithms and includes insulin adjust-
ment strategies for physical activity, illness, and when con-
suming alcohol.
It has been reported by the authors that the participants
experienced a rapid improvement of their insulin needs com-
pared to a control group using manual methods [16].
However, the authors provide no statistical evaluation. All
the users trusted the application’s calculations of insulin doses,
although its 90-day storage feature provided doctors with lim-
ited data regarding the patients.
IDM
The University of Alberta’s “IDM” for Android and Apple
devices is another T1DM application with features similar to
those of “RapidCalc,” plus a Web platform supporting view-
ing of diary statistics.
Clinical evaluation of the application It was tested on 31 pa-
tients, of whom only 18 completed the 4-week test period
[17]. Results are expressed as mean ± SD or median and
25th and 75th interquartile range (IQR). Student’s t test was
used to assess differences between groups and a signed rank
test when the normality test failed. Proportions were assessed
using the z test, and all analyses were performed using Sigma-
Stat (Systat Software, San Jose, CA, USA). The dropout rate
suggests a major weakness, namely, a possibly confusing lay-
out or users’ difficulty in understanding the insulin calculator.
The median HbA1c levels fell in a borderlinemanner from 8.1
(range 7.5 to 9.0) to 7.8% (6.9 to 8.3; P < 0.001) for those
completing the test.
Text messaging intervention (SMS)
SMS to improve glycemic control among patients
This approach was designed to motivate mobile phone users
to improve their health by receiving reminders about exercise
and blood tests and ways to plan better diets. The limitation of
this approach is that patients cannot monitor their health sta-
tus, and there is no interactive communication with the
healthcare providers. This approach was first introduced by
the Detroit Partnership Diabetes Lifestyle Intervention and
Health Sciences in Dhaka (Bangladesh) [18] and, while prov-
ing simple to use, left a lot to be desired.
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Clinical evaluation of the approach A total of 236 adult pa-
tients with T2DM (diagnosed within the previous 5 years)
on oral medication therapy with access to SMS and attend-
ing the outpatient clinic of the Bangladesh Institute of
Health Sciences in Dhaka, Bangladesh, were recruited
(September 2013–August 2014) and randomly assigned
to SMS intervention versus to standard care groups. Data
were collected through face-to-face interviews with a
structured questionnaire, anthropometric measurements,
and blood tests for HbA1c using standard procedures. A
total of 36 participants with missing HbA1c data were ex-
cluded from the analysis. All participants in the interven-
tion group received 90 SMSs, based on the principles of
behavioral learning theory, once a day, over a 6-month
period. The average age of the participants was 48 +
9.7 years, and 54.2% were female. The average HbA1c
levels at baseline was 8.4 + 2.6%. The mean difference of
HbA1c from baseline to after 6 months (primary end point)
was − 0.85 in the SMS group and − 0.18 in the control
group. The difference between means was − 0.66
(P < 0.0001). Post hoc subgroup analyses suggested that
the SMS intervention worked better in women and in those
with a baseline HbA1c 0.8% and those with a shorter du-
ration of diabetes.
REACH
The application “REACH” (Rapid Education/Encouragement
and Communications for Health) belongs to this category.
Clinical evaluation of the application Thirty-six participants
were recruited for the clinical evaluation with rather impres-
sive results [19]. The participants’ average age was 52.4, 56%
were female, and 63% were a racial or ethnic minority. About
half were taking insulin. The starting HbA1c levels were ap-
proximately 8.2%, which was suppressed to 7.5% by the end
of the trial period, while their weight loss averaged 5%.
Unfortunately, the authors provide no statistical evaluation.
It should be noted that similarly to the previous approach,
frequent face-to-face meetings with the health providers were
essential in order to obtain these results.
Discussion
The bant2 application appears to be the easiest to use. The
interface is in English, and it is available for both Android
andApple devices. It mainly aims at helping patients tomonitor
their daily food intake, weight gain or loss, fasting blood glu-
cose, and HbA1c. We have found that the application has sev-
eral shortcomings, including lack of a calories tracker, while the
data it can store remain within the device; hence, they are not
accessible to the healthcare providers. Unfortunately, the statis-
tical evaluation of the application is still missing, since the
evaluation is still in progress.
The NoomHealth application is available only for English-
speaking Android mobile users. It aims at educating the users
on various aspects of their condition. The power of this appli-
cation is that it provides a virtual coach (avatar) which delivers
Fig. 3 RapidCalc mobile application interface. The top left tab gives
input information. A rough daily estimate of consumed food/cal and
blood glucose metrics, plus other important information enabling a
calculation of the insulin dose required. A disadvantage is that it has no
calories tracker. The middle column shows insulin dose calculations at
different times; the right-hand column gives statistics for a specific period
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timely, tailored, and motivational guidance. In addition, this
application offers a 500,000+-item international food database
and a color-coded food calorie density list. A major shortcom-
ing of this application is the preliminary evaluation of the
application, which was tested only for 24 weeks on 62 over-
weight patients. The strength of this application is that it was
tested thoroughly by t test and ANOVA.
The DialBetics is a Japanese mobile application which is
similar to bant2. It stores data in a calendar and transmits them
automatically to the healthcare providers. The clinical efficacy
of this application is still elementary and needs to be im-
proved. Based on the application’s clinical statistics, the dif-
ference achieved in HbA1c appears to be borderline.
The Welltang is a Chinese Mandarin application for both
Apple and Android devices. It offers guidelines on a daily
basis regarding diet, exercise, medication, and blood glucose
levels. The performance of the Welltang is considered satis-
factory. From the statistical point of view, the authors used the
paired t test based on a 3-month follow-up. HbA1c decreased
by 1.95% in the intervention group versus 0.79% in the con-
trol group (P < 0.001).
The strength of the Diabetes Pal application is that it en-
ables users to send their glucose monitoring data directly to
the healthcare providers via several methods. The application
also helps with hypoglycemia episodes by guiding the pa-
tients. The main drawback of this application is that it can
only store FBG levels. Moreover, although the clinical evalu-
ation was conducted at the Singapore General Hospital, the
number of participants was small, there was no control group,
and the number of the chemical evaluated parameters limited.
The application PilAm Go4Health aims at helping patients
with T2DM to lose weight. It is similar to bant2 and
DialBetics. However, it does not store caloric intake and bio-
chemical parameters. The statistical evaluation of HbA1c and
BMI after 6 months showed the levels to be statistically sig-
nificantly decreased, with a P < 0.05.
The “ONEDROP”was developed for Apple devices and is
similar to the bant2, Welltang, and Diabetes Pal applications.
The additional feature which it provides is the live coaching
service by a CDE member for 24 h a day/5 days a week.
Moreover, the user can share his/her personal health records
and achievements with other users in order tomotivate or to be
motivated. The clinical evaluation was satisfactory for both
the study completers (P = 0.0003) and the active users
(P < 0.001).
The application “RapidCalc” was designed for English-
speaking Apple T1DM device users only. Mainly, this appli-
cation is an insulin dose calculator. It provides a statistical
analysis for a full 90-day record of insulin doses, statistical
analysis of carbohydrate intake, and glucose blood readings,
which can also be exported via email for archiving or further
analysis. On the other hand, major limitations were also
found, as it does not provide a database of food caloric intake Ta
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and it cannot collect activities and educate or motivate the
users. Unfortunately, the authors did not provide efficient sta-
tistical evaluation.
The IDM application, with similarities to the RapidCalc,
mainly also targets T1DMpatients. Unfortunately, it was eval-
uated in only 31 participants. The authors have used Student’s
t tests to assess the differences between groups. The high
dropout rate also suggests a major weakness, namely, a con-
fusing layout. The HbA1c levels dropped in a borderline
manner.
While some applications (Table 1) attempt to only educate
patients regarding diet, the Chinese “Weltang” also covers
medicinal requirements, a necessary feature for those patients
taking a multitude of medicines. Only three applications
(“DialBetics,” “Weltang,” “Diabetes Pal”) provide the person-
al health providers with feedback and not in a real time mode
and only after a certain period of time, during which the clin-
ical needs of each patient may have changed drastically. Only
the DROP One application provides real-time coaching by a
certified CDE. It is also noticeable that neither the “Noom
Health” nor the “PilAm Go4Health” applications track blood
glucose measurements, which are essential features for both
T1DM and T2DM patients.
Conclusions
All mobile applications presented in this review were de-
signed to assist patients at all stages of diabetes. They main-
ly focus on monitoring daily caloric intake, type of food
consumed, exercise, FBG, PPG, and medications intake.
On the other hand, applications targeting insulin adminis-
tration in either T1DM or T2DM patients concentrate main-
ly on the calculations of daily insulin units. Clearly, an ap-
plication providing both facilities would be more versatile
and clinically helpful. It is our impression that the sophisti-
cation level of the existing mobile applications for the
follow-up of diabetic patients is still insufficiently stream-
lined, and there is a limited level of interaction between
patients and health providers. The clinical evaluation of all
these applications has been based on a limited number of
patients, lack of parallel controls, for short periods of time,
and assessing few parameters.
All participants in the clinical trial experienced a lower-
ing of HbA1c levels by a significant degree. However, sev-
eral negative factors need to be considered, including lan-
guage barriers, a variety of database parameters, such as
calorie trackers, and non-inclusion of a real-time platform
enabling doctors to monitor their patients’ health status.
Clearly, there is some way to go until the appearance of
the ideal application that has all the necessary features
installed.
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